<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243514</url>
  </required_header>
  <id_info>
    <org_study_id>US-RNRE</org_study_id>
    <secondary_id>NSFC81370440</secondary_id>
    <nct_id>NCT02243514</nct_id>
  </id_info>
  <brief_title>Intravascular Ultrasound Evaluation of Renal Nerves in Different Diseases</brief_title>
  <official_title>Intravascular Ultrasound Evaluation of the Renal Nerves Remodeling in Different Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sympathetic hyperactivity is a causal or a promoting factor in many diseases, under these&#xD;
      conditions, some morphology changes due to the hyperactivity occur. Renal nerve is an&#xD;
      important part in the autonomic nervous system regulation, especially in cardiovascular&#xD;
      system, the modulation of the renal nerves used as a therapeutic strategy has been researched&#xD;
      across the world. The purpose of this study is to evaluate and quantify the morphology&#xD;
      changes in different diseases, make the modulation therapy more selective and effective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People eligible for this study will be divided into 4 groups according to the eligibility&#xD;
      criteria(Resistant Hypertension Group,Essential Hypertension Group, Chronic Heart Failure&#xD;
      Group and Control Group), about 15 objects for each, totally 60 objects are going to be&#xD;
      recruited.&#xD;
&#xD;
      Before the intravascular ultrasound examination, ambulatory blood pressure, ECG, plasma&#xD;
      catecholamine hormones, renin-angiotension-aldosterone, ect. will be measured. An&#xD;
      intravascular ultrasound examination will be taken after all of these have been done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number increase of Renal nerves in patients with sympathetic over-activity diseases</measure>
    <time_frame>A duration of the whole research stage, an expected average of 1/2 year</time_frame>
    <description>Total number of the renal nerve of each patient(automatic identification by the embedded software in the ultrasound imaging host/counting manually): Number of Nerve Bundles;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area increase of Renal nerves in patients with sympathetic over-activity diseases</measure>
    <time_frame>A duration of the whole research stage, an expected average of 1/2 year</time_frame>
    <description>Total area of the renal nerve (measured by ultrasound imaging host) of each patient: square millimeter (mm²)=∑= Nerve 1(length*width)+ Nerve 2(length*width)+ ......+ Nerve n(length*width);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The increase of the ratio of nerve area/artery wall area in patients with sympathetic over-activity diseases.</measure>
    <time_frame>A duration of the whole research stage, an expected average of 1/2 year</time_frame>
    <description>Renal artery area of each patient (measured by ultrasound imaging host): Square millimeter (mm²);&#xD;
Renal arterial wall area (measured by ultrasound imaging host) of each patient: Square millimeter (mm²);&#xD;
Total area of the renal nerve/Total renal artery area: percentage (%);&#xD;
Total area of the renal nerve/Total renal arterial wall area: percentage (%);</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events Related to The Intervention Procedure</measure>
    <time_frame>Participants will be followed for the duration of the operation time, an expected average of 0.5-1 hours</time_frame>
    <description>Renal arteriography will be carried out post operation to evaluate the possibility of renal artery injuries caused by this procedure, which including:&#xD;
Emerging renal artery dissection;&#xD;
Emerging renal artery stenosis, which will not improve by the intravascular injection of nitroglycerin;&#xD;
Emerging renal artery rupture or perforate;&#xD;
Contrast-induced nephropathy&#xD;
Any other complications related to this intervention procedure, such as catheter breakage, infection, hematoma ect.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Resistant hypertension</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Essential hypertension</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic heart failure</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, urine, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients who are going to take a vascular interventional examination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Resistant hypertension group&#xD;
&#xD;
               -  blood pressure remains above goal in spite of the concurrent use of three or more&#xD;
                  anti-hypertensive agents(including a diuretic) at adequate doses.&#xD;
&#xD;
               -  agrees to have the study procedure(s) performed and additional procedures and&#xD;
                  evaluations&#xD;
&#xD;
          2. Essential hypertension group&#xD;
&#xD;
               -  systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or&#xD;
                  current use of anti-hypertensive medication with a normal blood pressure or mean&#xD;
                  ambulatory blood pressure during the 24-hour≥130/80 mmHg.&#xD;
&#xD;
               -  not resistant to pharmacotherapy.&#xD;
&#xD;
               -  agrees to have the study procedure(s) performed and additional procedures and&#xD;
                  evaluations&#xD;
&#xD;
          3. Chronic heart failure group&#xD;
&#xD;
               -  New York Heart Association class II-III symptoms, or American College of&#xD;
                  Cardiology(ACC) / American Heart Association(AHA) heart failure classification&#xD;
                  B-C class of chronic heart failure.&#xD;
&#xD;
               -  currently or prior have the signs of heart failure, such as elevated jugular&#xD;
                  venous pressure, peripheral edema, pulmonary crepitations, ect.&#xD;
&#xD;
               -  Systolic left ventricular dysfunction as assessed by echocardiogram with left&#xD;
                  ventricular ejection fraction &lt; 40%.&#xD;
&#xD;
               -  agrees to have the study procedure(s) performed and additional procedures and&#xD;
                  evaluations&#xD;
&#xD;
          4. Control group&#xD;
&#xD;
               -  no history of arterial hypertension, heart failure and diabetes&#xD;
&#xD;
               -  going to take a vascular interventional examination during hospitalization&#xD;
&#xD;
               -  agrees to have the study procedure(s) performed and additional procedures and&#xD;
                  evaluations&#xD;
&#xD;
        All patients have full capacity for civil conduct and agree to sign the Medical Informed&#xD;
        Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hemodynamically or anatomically significant renal artery stenosis.&#xD;
&#xD;
          -  renal artery variation.&#xD;
&#xD;
          -  renal artery diameter &lt; 4 mm, trunk length &lt; 20 mm.&#xD;
&#xD;
          -  secondary hypertension with known causes and pseudo-hypertension.&#xD;
&#xD;
          -  has experienced myocardial infarction, unstable angina pectoris, or cerebrovascular&#xD;
             accident within 6 months.&#xD;
&#xD;
          -  has an implantable cardioverter defibrillator (ICD) or pacemaker.&#xD;
&#xD;
          -  requires respiratory support.&#xD;
&#xD;
          -  is pregnant or planning to be pregnant.&#xD;
&#xD;
          -  cardiovascular diseases with sever hemodynamic disorder.&#xD;
&#xD;
          -  type 1 diabetes mellitus.&#xD;
&#xD;
          -  currently enrolled in another investigational drug or device trial.&#xD;
&#xD;
          -  civil disability or limited capacity for civil conduct.&#xD;
&#xD;
          -  other conditions researchers considered unsuitable for enrolled in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology, the 2nd affiliated hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Huang, MD</last_name>
    <phone>0086-13508312022</phone>
    <email>huangjing@cqmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Huang, MD</last_name>
      <phone>0086-13508312022</phone>
      <email>huangjing@cqmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jing Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.</citation>
    <PMID>24678939</PMID>
  </reference>
  <reference>
    <citation>D'Elia E, Pascale A, Marchesi N, Ferrero P, Senni M, Govoni S, Gronda E, Vanoli E. Novel approaches to the post-myocardial infarction/heart failure neural remodeling. Heart Fail Rev. 2014 Sep;19(5):611-9. doi: 10.1007/s10741-013-9415-6. Review.</citation>
    <PMID>24292688</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2014</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Jing Huang</investigator_full_name>
    <investigator_title>Professor and Vice Director, Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Sympathetic hyperactivity</keyword>
  <keyword>Renal nerve</keyword>
  <keyword>Remodeling</keyword>
  <keyword>Nerve remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

